10x Genomics, Inc. Class A Common Stock (TXG) Financials
Key financial figures for 10x Genomics, Inc. Class A Common Stock (Q3 2026).
10x Genomics raised FY2026 revenue guidance to $625-635M from $610-630M after Q3 revenue of $150.7M (+1% YoY) with GAAP gross margin of 75% and Atera shipments underway. Revenue was $150.7M, up 1% from $149.0M a year earlier; products and services revenue rose 1% to $150.2M while license and royalty revenue fell to $0.5M from $1.0M. Consumables revenue rose to $134.3M from $127.9M (Spatial consumables $41.2M vs $35.4M, Single Cell $93.1M vs $92.5M), while instruments revenue fell to $6.9M from $12.0M and services rose to $9.0M from $8.1M. GAAP gross margin was 75% versus 67% a year earlier, primarily on lower inventory write-downs and product mix. On the outlook: Raised full-year 2026 revenue guidance to $625 million to $635 million from $610 million to $630 million; excluding non-recurring license and royalty revenue related to patent litigation settlements in both 2026 and 2025, this represents 4% to 6% growth over full-year 2025. Figures are for Q3 2026, as 10x Genomics Inc. reported them.
- Revenue
- $151M
- Net Income
- -$19M
- EPS
- $-0.15
- Total Assets
- $1.1B
- Operating Cash Flow
- $16M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $151M | -$19M | -$0.15 | -10.66% | $15M |
| Q2 FY2026 | $151M | -$18M | -$0.14 | -12.95% | $15M |
| Q1 FY2026 | $151M | -$13M | -$0.10 | -11.3% | $25M |
| Q4 FY2025 | $166M | -$16M | -$0.13 | -11.77% | $39M |
| Q3 FY2025 | $149M | -$27M | -$0.22 | -21.64% | $43M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $643M | -$44M | -$0.35 | -9.49% | $130M |
| FY2024 | $611M | -$183M | -$1.52 | -31.85% | -$6M |
| FY2023 | $619M | -$255M | -$2.18 | -42.88% | -$65M |
Frequently asked questions
What was 10x Genomics Inc.'s revenue last quarter?
10x Genomics Inc. reported revenue of $150.7 million for Q3 FY2026, up 1.1% from the same period a year earlier.
Is 10x Genomics Inc. profitable?
Not in its most recent reported period. 10x Genomics Inc. reported a net loss of $19.4 million for Q3 FY2026, a net margin of -12.89% on revenue.
How has 10x Genomics Inc.'s margin trended?
Operating margin was -10.66% in Q3 FY2026, compared with -21.64% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did 10x Genomics Inc. generate?
10x Genomics Inc. generated free cash flow of $14.9 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for 10x Genomics, Inc. Class A Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.